RecruitingNCT07509775

Integrated Traditional Chinese and Western Medicine for Ankylosing Spondylitis (AS): A Cohort Study Protocol Focusing on Spondyloarthritis Research Consortium of Canada (SPARCC) Scoring System

Integrated Traditional Chinese and Western Medicine for Ankylosing Spondylitis: A Cohort Study Protocol Focusing on Spondyloarthritis Research Consortium of Canada (SPARCC) Scoring System


Sponsor

China-Japan Friendship Hospital

Enrollment

210 participants

Start Date

Jan 19, 2026

Study Type

OBSERVATIONAL

Conditions

Summary

This study is a multicentre, ambidirectional, observational cohort study. The ambidirectional design incorporates both the collection of retrospective data from the three years prior to enrolment, and a prospective follow-up period of up to two years. The study is designed to evaluate the long-term effects of Integrated Medicine on radiographic progression in patients diagnosed with Ankylosing spondylitis (AS).


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria3

  • fulfill the 1984 modified New York criteria for ankylosing spondylitis or the 2009 Assessment of SpondyloArthritis International Society (ASAS) classification criteria for axial spondyloarthritis
  • age between 18 and 75 years
  • sign informed consent.

Exclusion Criteria5

  • diagnosis of other autoimmune diseases besides the disease under investigation (e.g., rheumatoid arthritis, Sjögren's syndrome, erythema nodosum, myositis, etc.)
  • pregnancy or lactation
  • comorbid severe cardiovascular or cerebrovascular diseases, hepatic or renal failure, or malignancy
  • spondyloarthritis related to enteropathic arthritis, psoriatic arthritis, or reactive arthritis
  • unable to provide data due to mental, language, or similar factors.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

China-Japan Friendship Hospital

Beijing, Beijing, China, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07509775


Related Trials